Alios BioPharma has signed an exclusive worldwide licensing agreement with Versitech to develop, manufacture and market medication to combat influenza viruses.

In addition, the companies have also entered into two other influenza-related, non-exclusive licence agreements and a sponsored research agreement.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Alios will sponsor collaborative research at the University of Hong Kong, as Versitech is its technology transfer company.

Alios BioPharma president and CEO Lawrence Blatt said that the compounds and technology derived from the deal will provide key therapeutic options to help improve patients infected from influenza virus.

Pharmaceutical Technology Excellence Awards - Have you nominated?

Nominations are now open for the prestigious Pharmaceutical Technology Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact. This is your chance to showcase your achievements, highlight industry advancements, and gain global recognition. Don't miss the opportunity to be honoured among the best - submit your nomination today!

Nominate Now